Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.
Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.

NCT06479954

Active Not RecruitingN/A

Sponsor: Pfizer

Conditions: Relapsed and Refractory Multiple Myeloma (RRMM)

Countries: Japan

To investigate the safety and efficacy in patients with relapsed and refractory multiple myeloma treated with elranatamab under the actual use.

Eligibility overview

Sex: ALL

Age: 16 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

Patients who have received at least one dose of elranatamab.
Locations (1)
  • Tokyo, Japan